Immucell Corp /De/ (ICCC) - Comprehensive Stock Analysis & Investment Research
Deep dive into Immucell Corp /De/'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Immucell Corp /De/ Investment Summary
When evaluating whether Immucell Corp /De/ (ICCC) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Immucell Corp /De/ (ICCC) operates within the Life Sciences sector, specifically in the In Vitro & In Vivo Diagnostic Substances industry. The company employs approximately 43 people. With a market capitalization of $57 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Immucell Corp /De/'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Immucell Corp /De/ along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Immucell Corp /De/ is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Immucell Corp /De/ (Stock Symbol: ICCC) is a prominent company operating within the Life Sciences sector, with a specific focus on the In Vitro & In Vivo Diagnostic Substances industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Immucell Corp /De/'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Immucell Corp /De/...
Sector & Industry Analysis
In-depth sector dynamics and industry context for Immucell Corp /De/...
Revenue & Growth Analysis
Immucell Corp /De/ generates annual revenues of $27 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Immucell Corp /De/...
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Immucell Corp /De/...
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Immucell Corp /De/...
Strategic Market Position
Immucell Corp /De/ strategically competes in the highly dynamic In Vitro & In Vivo Diagnostic Substances marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Immucell Corp /De/ competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-1 million , with year-over-year cash flow growth of 463.4%. Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 55.8% gross margin indicating healthy pricing power relative to direct production costs. This margin level suggests the company has successfully differentiated its products or services, allowing it to command prices meaningfully above input costs. Maintaining these margins requires ongoing investment in brand, technology, or other differentiating factors.
Operating margin of 16.0% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This healthy operating margin shows balanced investment in growth functions while maintaining reasonable profitability.
Asset Utilization Efficiency
Asset turnover ratio of 0.49x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.
Financial Strength & Leverage
Current ratio of 7.78 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.